期刊
JOURNAL OF DIABETES INVESTIGATION
卷 12, 期 4, 页码 668-671出版社
WILEY
DOI: 10.1111/jdi.13369
关键词
Bromocriptine; Continuous glucose monitoring; Prolactinoma
This study investigated the use of dopamine receptor agonist bromocriptine in treating type 2 diabetes in a female patient with a history of prolactinoma. The results showed that bromocriptine significantly improved the patient's glycemic control levels.
Dopamine receptor agonists are typically used to treat Parkinson's disease and certain pituitary tumors, such as prolactinoma or a growth hormone-producing tumor. A 53-year-old woman with a history of prolactinoma was referred to Kumamoto University Hospital (Kumamoto, Japan) with poorly controlled type 2 diabetes. Her glycated hemoglobin and serum prolactin levels were increased (8.8% and 160.3 ng/mL, respectively). Bromocriptine, a dopamine D(2)receptor agonist, was administered to reduce her serum prolactin level. Because bromocriptine-QR (quick release) has been approved for the treatment of type 2 diabetes mellitus in the USA, a continuous glucose monitoring system, FreeStyle Libre Pro, was utilized to examine the effect of bromocriptine on glycemic control. After the initial administration of bromocriptine, glucose levels were rapidly and dramatically ameliorated, and the time in range (70-180 mg/dL) improved from 90% between 1 week before and after the initial administration of bromocriptine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据